演題詳細

一般口演 / Oral Session

一般口演 100 (Oral Session 100) :節外性B細胞リンパ腫

print

日程
2013年10月13日(日)
時間
15:00 - 16:00
会場
第8会場 / Room No.8 (ロイトン札幌 2F ハイネス)
座長・司会
正木 康史 (Yasufumi Masaki):1
1:金沢医科大学 血液免疫内科学
 
前へ戻る

Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma

演題番号 : OS-3-148

市川 聡 (Satoshi Ichikawa):1、福原 規子 (Noriko Fukuhara):1、井上 あい (Ai Inoue):1、勝嶌 浩紀 (Hiroki Katsushima):2、大場 理恵 (Rie Ohba):1、勝岡 優奈 (Yuuna Katsuoka):1、大西 康 (Yasushi Onishi):1、山本 譲司 (Joji Yamamoto):3、佐々木 治 (Osamu Sasaki):4、野村 順 (Jun Nomura):5、福原 修 (Osamu Fukuhara):6、石澤 賢一 (Kenichi Ishizawa):1、一迫 玲 (Ryo Ichinohasama):2、張替 秀郎 (Hideo Harigae):1

1:Dept. of Hematol. & Rheumatol., Tohoku Univ., Sendai, Japan、2:Dept. of Hematopathol., Tohoku Univ., Sendai, Japan、3:Dept. of Int. Med., Sendai City Hosp., Sendai, Japan、4:Dept. of Hematol., Miyagi Pref. Cancer Center, Sendai, Japan、5:Dept. of Int. Med., NTT East Tohoku Hosp., Sendai, Japan、6:Dept. of Int. Med., Sendai Red Cross Hosp., Sendai, Japan

 

Primary adrenal lymphoma (PAL) is an extremely rare subtype of extranodal non-Hodgkin's lymphoma with poor prognosis. From 2008 to 2013 we had experienced eight cases of PAL and analyzed them retrospectively. The patients ranged in age from 50 to 85 years, with a median of 71 years. The overall male:female ratio was 7:1. They were all diagnosed as diffuse large B-cell lymphoma pathologically. The median largest tumor diameter at diagnosis was 62.5 mm. Bilateral adrenal involvement was confirmed in five patients. In two cases CNS infiltration was detected or suspected. Adrenal insufficiency, even if it is subclinical, was also seen in five bilateral PAL patients. B-symptom was observed in only one patient. All patients were treated by rituximab-containing chemotherapeutic regimen. The three patients, including the two patients in whom CNS infiltration was suspected or detected, received a full course of rituximab-containing regimen and CNS-directed therapy such as intravenous high-dose methotrexate (HD-MTX) or intrathecal injection of methotrexate; they are alive without disease progression or relapse. No patients died of progression of lymphoma. After a median follow-up of 16.1 months (range 1.9-45), overall survival rate of our seven PAL cases at one year was 57%. This yields that chemotherapeutic strategy including rituximab-containing regimen and CNS treatment for PAL cases in tolerable general condition is promising and can improve the prognosis of PAL.

前へ戻る